Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Barclays PLC (BCS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Barclays PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Barclays PLC trades at $27.87 (market cap $94.10B). The key difference: Barclays PLC is far larger — about 18.6× ACADIA Pharmaceuticals Inc.'s market cap, and Barclays PLC pays a 2.18% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BCS | |
|---|---|---|
Market Cap | $5.06B | $94.10B |
Sector | Health | Financials |
52-Week High | $29.39 | $28.56 |
52-Week Low | $20.06 | $19.36 |
Enterprise Value | $4.18B | — |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.
The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
